Literature DB >> 20466543

Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.

Jyothi Matharu1, Jun Oki, David R Worthen, Quentin R Smith, Peter A Crooks.   

Abstract

Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 have been synthesized and their affinities for the large neutral amino acid transporter (LAT1) of the blood-brain barrier have been determined to assess their potential for accessing the CNS via facilitated transport. Several analogs had K(i) values in the range 2.1-8.5 microM with greater affinities than that of either L-phenylalanine (K(i)=11 microM) or melphalan (K(i)=55 microM), but lower than DL-2-NAM-7 (K(i)=0.08 microM). The results indicate that regiospecific positioning of the mustard moiety on the aromatic ring in these analogs is very important for optimal affinity for the large neutral amino acid transporter, and that conformational restriction of the DL-2-NAM-7 molecule in benzonorbornane and indane analogs leads to 25- to 60-fold loss, respectively, in affinity. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466543      PMCID: PMC3725995          DOI: 10.1016/j.bmcl.2010.04.086

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

Review 1.  Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2.

Authors:  Eva M del Amo; Arto Urtti; Marjo Yliperttula
Journal:  Eur J Pharm Sci       Date:  2008-07-05       Impact factor: 4.384

Review 2.  Transport of glutamate and other amino acids at the blood-brain barrier.

Authors:  Q R Smith
Journal:  J Nutr       Date:  2000-04       Impact factor: 4.798

3.  Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system.

Authors:  N H Greig; S Momma; D J Sweeney; Q R Smith; S I Rapoport
Journal:  Cancer Res       Date:  1987-03-15       Impact factor: 12.701

4.  Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio.

Authors:  R Lewensohn; J Hansson; U Ringborg; H Ehrsson
Journal:  Eur J Cancer Clin Oncol       Date:  1987-06

5.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.

Authors:  W H Oldendorf
Journal:  Am J Physiol       Date:  1971-12

6.  An in situ brain perfusion technique to study cerebrovascular transport in the rat.

Authors:  Y Takasato; S I Rapoport; Q R Smith
Journal:  Am J Physiol       Date:  1984-09

7.  Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier.

Authors:  Y Takada; D T Vistica; N H Greig; D Purdon; S I Rapoport; Q R Smith
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

8.  Leucine enkephalin analogues containing a conformationally restrained N-terminal amino acid residue.

Authors:  T Deeks; P A Crooks; R D Waigh
Journal:  J Pharm Sci       Date:  1984-04       Impact factor: 3.534

9.  Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.

Authors:  Y Takada; N H Greig; D T Vistica; S I Rapoport; Q R Smith
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Synthesis and analgesic properties of two leucine-enkephalin analogues containing a conformationally restrained N-terminal tyrosine residue.

Authors:  T Deeks; P A Crooks; R D Waigh
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446

View more
  6 in total

1.  Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).

Authors:  Huan-Chieh Chien; Claire Colas; Karissa Finke; Seth Springer; Laura Stoner; Arik A Zur; Brooklynn Venteicher; Jerome Campbell; Colton Hall; Andrew Flint; Evan Augustyn; Christopher Hernandez; Nathan Heeren; Logan Hansen; Abby Anthony; Justine Bauer; Dimitrios Fotiadis; Avner Schlessinger; Kathleen M Giacomini; Allen A Thomas
Journal:  J Med Chem       Date:  2018-08-10       Impact factor: 7.446

2.  Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods.

Authors:  Natesh Singh; Mariafrancesca Scalise; Michele Galluccio; Marcus Wieder; Thomas Seidel; Thierry Langer; Cesare Indiveri; Gerhard F Ecker
Journal:  Int J Mol Sci       Date:  2018-12-21       Impact factor: 5.923

3.  Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1).

Authors:  Natesh Singh; Bruno O Villoutreix; Gerhard F Ecker
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

4.  The Evaluation of l-Tryptophan Derivatives as Inhibitors of the l-Type Amino Acid Transporter LAT1 (SLC7A5).

Authors:  Julien Graff; Jennifer Müller; Anna Sadurní; Matthias Rubin; Inês André Canivete Cuissa; Claudia Keller; Marco Hartmann; Simon Singer; Jürg Gertsch; Karl-Heinz Altmann
Journal:  ChemMedChem       Date:  2022-08-10       Impact factor: 3.540

Review 5.  Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.

Authors:  Natesh Singh; Gerhard F Ecker
Journal:  Int J Mol Sci       Date:  2018-04-24       Impact factor: 5.923

Review 6.  L-Type amino acid transporter 1 as a target for drug delivery.

Authors:  Elena Puris; Mikko Gynther; Seppo Auriola; Kristiina M Huttunen
Journal:  Pharm Res       Date:  2020-05-06       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.